X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) issued its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), Zacks reports.

X4 Pharmaceuticals Stock Performance

XFOR opened at $0.30 on Tuesday. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a market cap of $51.23 million, a PE ratio of -3.28 and a beta of 0.39. The business has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.53. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

Insider Transactions at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 over the last three months. Company insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE raised its stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the quarter. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent reporting period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.